EP0091762B1 - Process for the production of an iron-selenium trace element solution - Google Patents

Process for the production of an iron-selenium trace element solution Download PDF

Info

Publication number
EP0091762B1
EP0091762B1 EP83301863A EP83301863A EP0091762B1 EP 0091762 B1 EP0091762 B1 EP 0091762B1 EP 83301863 A EP83301863 A EP 83301863A EP 83301863 A EP83301863 A EP 83301863A EP 0091762 B1 EP0091762 B1 EP 0091762B1
Authority
EP
European Patent Office
Prior art keywords
selenium
iron
ferric
solution
sodium selenite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP83301863A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0091762A1 (en
Inventor
Timo Juhani Pekkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Publication of EP0091762A1 publication Critical patent/EP0091762A1/en
Application granted granted Critical
Publication of EP0091762B1 publication Critical patent/EP0091762B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof

Definitions

  • This invention provides a new preparation of and a new method for the production of trace element solutions containing iron and selenium for the treatment of animals and man.
  • iron and selenium In order to meet the iron and selenium requirements of a growing animal from birth onwards, piglets are today given iron and selenium, at the age of 1 ... 3 days, usually in the form of an intramuscular or subcutaneous injection. Iron is usually given as ferric dextran, corresponding to 100 ... 200 mg of iron. Selenium is administered as sodium selenite at a dosage of approx. 0.06 mg Se 14/kg. Since the halfline of selenium in the organism is short and excess is not stored to any appreciable degree, a single selenium injection gives only a short-term protection.
  • any physiologically assimilable soluble selenium compound can be used in the new preparation.
  • Sodium selenite and selenium dioxide are especially suitable.
  • iron-polysaccharide complexes are ferric dextran and ferric polymaltose.
  • the iron and selenium contents of the solution can be varied within a considerable range, according to whether the deficiency states are due primarily to lack of iron or to lack of selenium.
  • the ratio of selenium to iron can be from 10- 5 to 10- 1 : 1 by weight, a ratio of 10-3 3 to 10 - 2 : 1 being especially suitable.
  • the solution is prepared simply by dissolving the selenium compound in an aqueous solution of iron polysaccharide (or corresponding hydrolysate) and adding water as necessary.
  • the powdered substances can be mixed and water (or some other solvent) added later prior to use, or else a paste prepared. If desirable, other substances such as vitamin E can be added to the mixture.
  • the new type of preparation containing sodium selenite and ferric dextran was administered intramuscularly to three pigs, weight 15... 25 kg, suffering from selenium deficiency. Another three pigs suffering form selenium deficiency were given the same doese of sodium selenite. Serum selenium content and glutathione peroxidase enzyme activity were determined as a measure of the bioactivity of selenium in the organism. It was found that both the selenium content and glutathione peroxidase (gSH-Px) activity were significantly higher in the pigs given the preparation than in those given only selenium (Table 1). All the pigs were on the same diet throughout the test period.
  • the iron-selenium preparation provides a clearly observable increase in selenium bioactivity.
  • the men bioactivity in animals given selenium alone was 926 IU/1, whereas that in animals given the iron-selenium preparation was 1432 IU/1.
  • the corresponding figures were 518 IU/1 and 754 IU/1.
  • the serum selenium level also remained considerably elevated.
  • the serum selenium level of animals given the preparation was unchanged after 15 days, whereas that of animals given selenium alone remained elevated for only 8 days.
  • Sodium selenite corresponding 150 mg selene was dissolved in 5 ml sterile water and the solution was added to the solution of ferric dextran hydrolysate.
  • the solution was limited with sterile water to 1 liter ans passed through a filtermembrane or glasclinker for removing the particles.
  • the filtrate was filled in glass-ampoule or injectionbottles sterilized with hot-air. The ready-packed injection solutions was sterilized by autoclaving.
  • Ferric hydroxydipolymaltose complex corresponding 100 mg of ferric was dissolved in 500 ml sterile water and sodium selenite was added. The solution was limited with sterile water to 1 liter, it was filtred and filled to its receptacles and sterilized.
  • composition The injection solution was prepared as in example 1.
  • a homogeneous powder-mixture was prepared by known means.
  • the powder-mixture can be granulated with solvents.
  • Selene and ferric compounds was dissolved in a small part of water. Polyethyleneglycol was added in the water solution with effective mixing until the paste was formed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP83301863A 1982-04-07 1983-03-31 Process for the production of an iron-selenium trace element solution Expired EP0091762B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI821233 1982-04-07
FI821233A FI65913C (fi) 1982-04-07 1982-04-07 Foerfarande foer framstaellning av jaern och selen innehaollande spaoraemnespreparat

Publications (2)

Publication Number Publication Date
EP0091762A1 EP0091762A1 (en) 1983-10-19
EP0091762B1 true EP0091762B1 (en) 1985-07-10

Family

ID=8515330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83301863A Expired EP0091762B1 (en) 1982-04-07 1983-03-31 Process for the production of an iron-selenium trace element solution

Country Status (12)

Country Link
US (1) US4476114A (cs)
EP (1) EP0091762B1 (cs)
AU (1) AU553154B2 (cs)
CS (1) CS240957B2 (cs)
DD (1) DD209611A5 (cs)
DE (1) DE3360380D1 (cs)
DK (1) DK156122C (cs)
FI (1) FI65913C (cs)
HU (1) HU188446B (cs)
IE (1) IE54475B1 (cs)
PL (1) PL138117B1 (cs)
ZA (1) ZA832045B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE440591B (sv) * 1983-06-14 1985-08-12 Cederroths Ab Mineralsaltblandning innehallande selen
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US5000957A (en) * 1984-03-19 1991-03-19 Alza Corporation Dispenser comprising hydrophilic osmopolymer
SE500971C2 (sv) * 1992-08-25 1994-10-10 Kemira Kemi Ab Användning av en sulfit- eller selenitjonproducerande substans för beredning av ett medel med skatolinhiberande verkan
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
RU2176916C1 (ru) * 2001-01-22 2001-12-20 Новицкий Юрий Алексеевич Селеновое гликопротеиновое элементорганическое вещество, обладающее иммуностимулирующим действием (его варианты)
RU2242233C1 (ru) * 2003-12-15 2004-12-20 Новицкий Юрий Алексеевич Наномолекулярное селенопротеиновое органическое вещество, обладающее активным иммунотропным и метаболическим действием
RU2242235C1 (ru) * 2003-12-29 2004-12-20 Новицкий Юрий Алексеевич Наномолекулярное селенотерпенопротеиновое средство и способ лечения больных с зависимостью от психоактивных веществ
CN107519198A (zh) * 2017-07-21 2017-12-29 南通市第人民医院 一种右旋糖酐铁注射液及其制备方法
EP3578182A1 (en) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions
CN109852648B (zh) * 2019-04-11 2022-08-09 广西大学 酶法制备右旋糖酐硒聚物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820740A (en) * 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
US3022221A (en) * 1959-04-16 1962-02-20 Chemicals Inc Iron hydrogenated dextran
US3076798A (en) * 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
US3829566A (en) * 1964-03-17 1974-08-13 Chromalloy Pharma Inc Method for control of white muscle disease
GB2090133A (en) * 1980-11-12 1982-07-07 Patterson Janice Anne Veterinary Composition containing Vitamin E and Selenium Compounds

Also Published As

Publication number Publication date
US4476114A (en) 1984-10-09
FI821233L (fi) 1983-10-08
DD209611A5 (de) 1984-05-16
FI65913B (fi) 1984-04-30
CS229183A2 (en) 1985-06-13
EP0091762A1 (en) 1983-10-19
IE830790L (en) 1983-10-07
AU1279883A (en) 1983-10-13
FI65913C (fi) 1984-08-10
DK143683A (da) 1983-10-08
FI821233A0 (fi) 1982-04-07
DE3360380D1 (en) 1985-08-14
DK143683D0 (da) 1983-03-29
DK156122C (da) 1989-11-20
ZA832045B (en) 1983-12-28
CS240957B2 (en) 1986-03-13
IE54475B1 (en) 1989-10-25
PL138117B1 (en) 1986-08-30
PL241367A1 (en) 1984-07-16
HU188446B (en) 1986-04-28
DK156122B (da) 1989-06-26
AU553154B2 (en) 1986-07-03

Similar Documents

Publication Publication Date Title
Pories et al. Acceleration of wound healing in man with zinc sulphate given by mouth
EP0226332B1 (en) Veterinary compositions
EP0091762B1 (en) Process for the production of an iron-selenium trace element solution
US3491187A (en) Iron salt-antibiotic compositions and use thereof
Sharma et al. Effects of levels of protein and gossypol, and length of feeding period on the accumulation of gossypol in tissues of swine
Read et al. Studies with 15 N-labeled ammonia and urea in the malnourished child
RU2130312C1 (ru) Лечебный препарат, обладающий бактерицидным и вирулицидным действием - йодомидол
Woodard et al. Xanthan gum: safety evaluation by two-year feeding studies in rats and dogs and a three-generation reproduction study in rats
RU2521369C1 (ru) Препарат для стимуляции обменных процессов, профилактики и лечения желудочно-кишечных заболеваний телят в ранний постнатальный период
US4076803A (en) Synergistic combination of metal proteinates with beta-chlorovinyl dialkyl phosphates
JP2004329110A (ja) 家畜動物用予防及び／又は治療剤
Bremner Pathogenetic factors in experimental bovine oesophagostomosis: IV. Exudative enteropathy as a cause of hypoproteinemia
Neumann et al. Unidentified growth factor (s) needed for optimum growth of newborn pigs
Suttle et al. Effect of intake of copper, molybdenum and sulphate on copper metabolism in sheep: IV. Production of congenital and delayed swayback
RU2368391C1 (ru) Способ получения комплексного иммуностимулирующего препарата для повышения естественной резистентности организма животных
Stanley et al. Cobalt polycythemia. II. Relative effects of oral and subcutaneous administration of cobaltous chloride
US3065138A (en) Therapeutic preparations of elemental iron
JPH07118162A (ja) 家畜用経口投与組成物
US3085936A (en) Gastro-enteritis-diarrheal syndrome treatment
Basu Effects of estrogen and progestogen on the ascorbic acid status of female guinea pigs
Hsia et al. Hepatolenticular degeneration: The comparative effectiveness of D-penicillamine, potassium sulfide, and diethyldithiocarbamate as decoppering agents
RU2200013C2 (ru) Лекарственное средство для лечения и профилактики болезней, вызываемых недостаточностью селена в организме сельскохозяйственных животных
Liesegang et al. Unexpected outcome after two consecutive infusions of disodium EDTA. in Dairy Cows
RU2302873C2 (ru) Препарат для профилактики и лечения анемии, коррекции нарушений обмена веществ у сельскохозяйственных животных
Svoboda et al. Iron deficiency in suckling piglets: Parenteral and oral iron administration to piglets

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE DE FR GB IT NL

17P Request for examination filed

Effective date: 19831104

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE DE FR GB IT NL

REF Corresponds to:

Ref document number: 3360380

Country of ref document: DE

Date of ref document: 19850814

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19920309

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19920312

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920318

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920330

Year of fee payment: 10

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19920331

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19930331

Ref country code: BE

Effective date: 19930331

BERE Be: lapsed

Owner name: ORION-YHTYMA OY

Effective date: 19930331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19931001

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19931130

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19930331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19931201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST